423 related articles for article (PubMed ID: 26369960)
41. Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor.
Concha NO; Janson CA; Rowling P; Pearson S; Cheever CA; Clarke BP; Lewis C; Galleni M; Frère JM; Payne DJ; Bateson JH; Abdel-Meguid SS
Biochemistry; 2000 Apr; 39(15):4288-98. PubMed ID: 10757977
[TBL] [Abstract][Full Text] [Related]
42. Structural and Mutagenic Analysis of Metallo-β-Lactamase IMP-18.
Furuyama T; Nonomura H; Ishii Y; Hanson ND; Shimizu-Ibuka A
Antimicrob Agents Chemother; 2016 Sep; 60(9):5521-6. PubMed ID: 27381398
[TBL] [Abstract][Full Text] [Related]
43. Asp120Asn mutation impairs the catalytic activity of NDM-1 metallo-β-lactamase: experimental and computational study.
Chen J; Chen H; Zhu T; Zhou D; Zhang F; Lao X; Zheng H
Phys Chem Chem Phys; 2014 Apr; 16(14):6709-16. PubMed ID: 24584846
[TBL] [Abstract][Full Text] [Related]
44. Mimicking natural evolution in metallo-beta-lactamases through second-shell ligand mutations.
Tomatis PE; Rasia RM; Segovia L; Vila AJ
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):13761-6. PubMed ID: 16172409
[TBL] [Abstract][Full Text] [Related]
45. Biochemical characterization of New Delhi metallo-β-lactamase variants reveals differences in protein stability.
Makena A; Brem J; Pfeffer I; Geffen RE; Wilkins SE; Tarhonskaya H; Flashman E; Phee LM; Wareham DW; Schofield CJ
J Antimicrob Chemother; 2015 Feb; 70(2):463-9. PubMed ID: 25324420
[TBL] [Abstract][Full Text] [Related]
46. Carbapenem Use Is Driving the Evolution of Imipenemase 1 Variants.
Cheng Z; Bethel CR; Thomas PW; Shurina BA; Alao JP; Thomas CA; Yang K; Marshall SH; Zhang H; Sturgill AM; Kravats AN; Page RC; Fast W; Bonomo RA; Crowder MW
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468463
[TBL] [Abstract][Full Text] [Related]
47. Kinetic and crystallographic studies of extended-spectrum GES-11, GES-12, and GES-14 β-lactamases.
Delbrück H; Bogaerts P; Kupper MB; Rezende de Castro R; Bennink S; Glupczynski Y; Galleni M; Hoffmann KM; Bebrone C
Antimicrob Agents Chemother; 2012 Nov; 56(11):5618-25. PubMed ID: 22908160
[TBL] [Abstract][Full Text] [Related]
48. Computational modelling of potential Zn-sensitive non-β-lactam inhibitors of imipenemase-1 (IMP-1).
Ayipo YO; Ahmad I; Alananzeh W; Lawal A; Patel H; Mordi MN
J Biomol Struct Dyn; 2023 Nov; 41(19):10096-10116. PubMed ID: 36476097
[TBL] [Abstract][Full Text] [Related]
49. Crystal structure of IMP-2 metallo-β-lactamase from Acinetobacter spp.: comparison of active-site loop structures between IMP-1 and IMP-2.
Yamaguchi Y; Matsueda S; Matsunaga K; Takashio N; Toma-Fukai S; Yamagata Y; Shibata N; Wachino J; Shibayama K; Arakawa Y; Kurosaki H
Biol Pharm Bull; 2015; 38(1):96-101. PubMed ID: 25744464
[TBL] [Abstract][Full Text] [Related]
50. New mutations in ADC-type β-lactamases from Acinetobacter spp. affect cefoxitin and ceftazidime hydrolysis.
Pérez A; Pérez-Llarena FJ; García P; Kerff F; Beceiro A; Galleni M; Bou G
J Antimicrob Chemother; 2014 Sep; 69(9):2407-11. PubMed ID: 24845871
[TBL] [Abstract][Full Text] [Related]
51. Hydroxyl groups in the (beta)beta sandwich of metallo-beta-lactamases favor enzyme activity: a computational protein design study.
Oelschlaeger P; Mayo SL
J Mol Biol; 2005 Jul; 350(3):395-401. PubMed ID: 15946681
[TBL] [Abstract][Full Text] [Related]
52. Structural Basis of Metallo-β-Lactamase Inhibition by Captopril Stereoisomers.
Brem J; van Berkel SS; Zollman D; Lee SY; Gileadi O; McHugh PJ; Walsh TR; McDonough MA; Schofield CJ
Antimicrob Agents Chemother; 2016 Jan; 60(1):142-50. PubMed ID: 26482303
[TBL] [Abstract][Full Text] [Related]
53. Broad-Spectrum Inhibitors against Class A, B, and C Type β-Lactamases to Block the Hydrolysis against Antibiotics: Kinetics and Structural Characterization.
Farhat N; Gupta D; Ali A; Kumar Y; Akhtar F; Kulanthaivel S; Mishra P; Khan F; Khan AU
Microbiol Spectr; 2022 Oct; 10(5):e0045022. PubMed ID: 36069578
[TBL] [Abstract][Full Text] [Related]
54. Hydroxyl groups in the betabeta sandwich of metallo-beta-lactamases favor enzyme activity: Tyr218 and Ser262 pull down the lid.
Oelschlaeger P; Pleiss J
J Mol Biol; 2007 Feb; 366(1):316-29. PubMed ID: 17157873
[TBL] [Abstract][Full Text] [Related]
55. Heterogeneous hydrolytic features for OXA-48-like β-lactamases.
Oueslati S; Nordmann P; Poirel L
J Antimicrob Chemother; 2015 Apr; 70(4):1059-63. PubMed ID: 25583748
[TBL] [Abstract][Full Text] [Related]
56. Extended-spectrum beta-lactamases: structure and kinetic mechanism.
Page MG
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():63-74. PubMed ID: 18154529
[TBL] [Abstract][Full Text] [Related]
57. Novel IMP-1 metallo-beta-lactamase inhibitors can reverse meropenem resistance in Escherichia coli expressing IMP-1.
Moloughney JG; D Thomas J; Toney JH
FEMS Microbiol Lett; 2005 Feb; 243(1):65-71. PubMed ID: 15668002
[TBL] [Abstract][Full Text] [Related]
58. An in silico approach for understanding the molecular evolution of clinically important metallo-beta-lactamases.
Pal A; Tripathi A
Infect Genet Evol; 2013 Dec; 20():39-47. PubMed ID: 23954421
[TBL] [Abstract][Full Text] [Related]
59. Kinetic Study of Laboratory Mutants of NDM-1 Metallo-β-Lactamase and the Importance of an Isoleucine at Position 35.
Marcoccia F; Bottoni C; Sabatini A; Colapietro M; Mercuri PS; Galleni M; Kerff F; Matagne A; Celenza G; Amicosante G; Perilli M
Antimicrob Agents Chemother; 2016 Apr; 60(4):2366-72. PubMed ID: 26856833
[TBL] [Abstract][Full Text] [Related]
60. A multiscale approach to predict the binding mode of metallo beta-lactamase inhibitors.
Gervasoni S; Spencer J; Hinchliffe P; Pedretti A; Vairoletti F; Mahler G; Mulholland AJ
Proteins; 2022 Feb; 90(2):372-384. PubMed ID: 34455628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
